Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer

Ryoichi Katsube¹, Kazuhiro Noma¹⁺, Toshiaki Ohara¹⁺, Noriyuki Nishiwaki¹, Teruki Kobayashi¹, Satoshi Komoto¹, Hiroaki Sato¹, Hajime Kashima¹, Takuya Kato¹, Satoru Kikuchi¹, Hiroshi Tazawa¹⁺,³, Shunsuke Kagawa¹, Yasuhiro Shirakawa¹, Hiroshi Tazawa¹,³, Shunsuke Kagawa¹, Yasuhiro Shirakawa¹, Hisataka Kobayashi⁴ & Toshiyoshi Fujiwara¹

Cancer-associated fibroblasts (CAFs) have an important role in the tumor microenvironment. CAFs have the multifunctionality which strongly support cancer progression and the acquisition of therapeutic resistance by cancer cells. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that uses a highly selective monoclonal antibody (mAb)-photosensitizer conjugate. We developed fibroblast activation protein (FAP)-targeted NIR-PIT, in which IR700 was conjugated to a FAP-specific antibody to target CAFs (CAFs-targeted NIR-PIT: CAFs-PIT). Thus, we hypothesized that the control of CAFs could overcome the resistance to conventional chemotherapy in esophageal cancer (EC). In this study, we evaluated whether EC cell acquisition of stronger malignant characteristics and refractoriness to chemoradiotherapy are mediated by CAFs. Next, we assessed whether the resistance could be rescued by eliminating CAF stimulation by CAFs-PIT in vitro and in vivo. Cancer cells acquired chemoradiotherapy resistance via CAF stimulation in vitro and 5-fluorouracil (FU) resistance in CAF-coinoculated tumor models in vivo. CAF stimulation promoted the migration/invasion of cancer cells and a stem-like phenotype in vitro, which were rescued by elimination of CAF stimulation. CAFs-PIT had a highly selective effect on CAFs in vitro. Finally, CAF elimination by CAFs-PIT in vivo demonstrated that the combination of 5-FU and NIR-PIT succeeded in producing 70.9% tumor reduction, while 5-FU alone achieved only 13.3% reduction, suggesting the recovery of 5-FU sensitivity in CAF-rich tumors. In conclusion, CAFs-PIT could overcome therapeutic resistance via CAF elimination. The combined use of novel targeted CAFs-PIT with conventional anticancer treatments can be expected to provide a more effective and sensible treatment strategy.

Abbreviations
APC  Antibody-photosensitizer conjugate
CAF  Cancer-associated fibroblast
CM  Conditioned medium
DMEM  Dulbecco’s modified eagle medium
EC  Esophageal carcinoma
ECM  Extracellular matrix
EMT  Epithelial mesenchymal transition
EPR  Enhanced permeability and retention

¹Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. ²Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. ³Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan. ⁴Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, MD, USA. *email: knoma@md.okayama-u.ac.jp
Stromal cells are strongly involved in the progression of cancer cells, and among stromal cells, cancer-associated fibroblasts (CAFs) have been reported to have an important role in the tumor microenvironment. In the past, several studies have demonstrated the multifunctional potential of CAFs, as they profoundly support cancer growth, invasion, metastasis, and acquisition of therapeutic resistance in cancer cells. Of note, recent studies have shown the immunosuppressive effects of CAFs on the immune response, and we also reported that CAFs regulated immunosuppressive tumor-infiltrating lymphocyte populations via interleukin (IL)-6 in the tumor microenvironment.

Esophageal cancer (EC) is known to be an aggressive malignant tumor. Although many treatment modalities for EC have been developed, the Comprehensive Registry of Esophageal Cancer in Japan has reported that the 5-year survival rates of patients treated using esophagectomy with concurrent chemotherapy, radiotherapy, alone or chemoradiotherapy were 6.3%, 24.9% and 32.4%, respectively, which are not satisfactory outcomes and are in part considered to be due to tumor acquisition of therapeutic resistance. Various mechanisms have been proposed, and some studies have indicated the possible involvement of CAFs. Thus, overcoming therapeutic resistance is one of the challenges in our efforts, and the development of novel therapeutic approaches is needed to improve the prognosis of EC patients.

Concerning therapeutic resistance associated with the tumor stroma, some studies have already reported that CAFs promote epithelial–mesenchymal transition (EMT) and stem-like characteristics in cancer cells by secreting soluble factors, such as transforming growth factor-beta (TGF-β) and IL-6. Furthermore, it has been reported that not only such indirect factors but also direct influences, such as cell-to-cell contact and the increased internal pressure of a CAF-rich stroma, contribute to resistance. In this way, CAFs support tumor acquisition of therapeutic resistance and tumor growth. Thus, many types of therapeutics targeting stromal cells have been investigated; however, CAFs have not yet been established as sufficient treatment targets.

CAFs express several markers, such as α-smooth muscle actin (αSMA), fibroblast stimulating protein-1 (FSP-1), platelet-derived growth factor (PDGFR) α, and PDGFRβ. Of those markers, we identified a specific surface marker, fibroblast activation protein (FAP), to target CAFs. FAP is a type II cell surface-bound transmembrane glycoprotein expressed on the cell surface of activated fibroblasts in the reactive stroma of epithelial cancers and the granulation tissue of healing wounds. Interestingly, FAP is expressed in the stroma of more than 90% of human cancers and has an important role in tumor progression, with high FAP tumor expression being associated with a poor prognosis. Our previous reports also demonstrated that FAP-positive cells were strongly related to lymph node metastasis and correlated with shortened survival in EC. Based on those reports, the target molecule FAP is considered to be the most effective marker due to its specificity and malignant relations, even though CAFs express several markers and exhibit heterogeneity.

Near-infrared photoimmunotherapy (NIR-PIT), which was introduced by Mitsunaga et al. in 2011, is a novel cancer treatment that uses a highly selective monoclonal antibody (mAb)-photosensitizer conjugate (APC). NIR-PIT is a molecularly targeted phototherapy for specific cells based on injecting a conjugate of IRdye700DX (IRD700, silicaporphyrin derivative), and a monoclonal antibody that recognizes an expressed antigen on the target cell surface. Once the antibody-IRD700 conjugate is bound to its target, subsequent local exposure to NIR light causes physical changes in the shape of antibody antigen complexes that are thought to induce physical stress within the cellular membrane leading to increases in transmembrane water flow that eventually lead to cell bursting, also known as an immunogenic cell death (ICD), in contrast to most other treatments that result in apoptosis. ICD rapidly mature dendritic cells adjacent to dying cancer cells, resulting in re-education and subsequent proliferation of CD8+ T cells against a variety of released cancer antigens, which amplifies the therapeutic

| FACS | Fluorescence-activated cell sorting |
| FAP | Fibroblast activation protein |
| FBS | Fetal bovine serum |
| FEF3 | Fetal esophageal fibroblasts |
| FSP1 | Fibroblast-specific protein 1 |
| 5-FU | 5-Fluouracil |
| GFP | Green fluorescent protein |
| ICD | Immunogenic cell death |
| IL-6 | Interleukin-6 |
| mAB | Monoclonal antibody |
| NIR | Near infrared |
| PBS | Phosphate-buffered saline |
| PDGFR | Platelet-derived growth factor receptor |
| PIT | Photoimmunotherapy |
| RT | Room temperature |
| SEM | Standard error of the mean |
| SMA | Smooth muscle actin |
| SUPR | Superenhanced permeation and retention effect |
| TGF | Transforming growth factor |
| VEGF | Vascular endothelial growth factor |
| WB | Western blotting |
| XTT | Sodium 2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium |
effect of NIR-PIT\(^{38,39}\). NIR-PIT is quite different from the conventional photodynamic therapy (PDT), which uses porphyrin derivatives to produce reactive oxygen species in the cells to induce apoptosis and cytotoxic effect\(^{40}\). Although recent studies have shown that PDT also induces ICD limited to a few photosensitizers\(^3\), the induction of host immunity through ICD is what makes NIR-PIT not only a local therapy but also a systemic therapy and is the advantage of NIR-PIT over PDT.

NIR-PIT and PDT are similar in that they induce cytotoxicity by irradiating light on photosensitizers that have accumulated in the tumor. However, unlike PDT, which allows some accumulation of photosensitizers in normal tissues, NIR-PIT selectively binds to specific antigens, leading to selective killing of target cells without destroying the surrounding cells. There are already several reports on NIR-PIT targeting various cells, including epithelial cancer cells and immune cells\(^{32-40}\). We also have been attracted to NIR-PIT as a CAFs-specific targeted therapy and developed FAP-targeted NIR-PIT, in which IR700 was conjugated to a FAP-specific antibody to target FAP positive cells. Recently, we successfully demonstrated a promising inhibitory effect on CAFs in EC\(^7\). Given the above information, as the next challenge of CAFs-targeted NIR-PIT (CAFs-PIT), we hypothesized that the elimination of CAFs could overcome the resistance to chemoradiotherapy described above.

In this work, we aimed to verify that CAFs-PIT could overcome the resistance to chemoradiotherapy in EC. First, we assessed whether EC cells acquire stronger malignant characteristics under the influence of CAFs and are refractory to chemotherapy and radiotherapy. Next, we determined whether the treatment resistance of these carcinoma cells could be rescued under normal conditions without CAF stimulation in vitro, and finally, we evaluated whether therapeutic sensitivity could be improved by CAFs-PIT therapy in vivo.

**Results**

**CAFs drive resistance to conventional therapy in tumor cells.** To evaluate the influence of CAFs on the therapeutic resistance of cancer cells, we performed a cell viability assay with tumor cells stimulated by CAFs. First, we analyzed the resistance to chemotherapy (5-fluoreuracil (5-FU) or docetaxel). After 2 days of stimulation with conditioned medium (CM) from CAFs (CM/CAF\(^{TE4}\) or CM/CAF\(^{OE19}\)), TE4 and OE19 cells demonstrated more resistance to chemotherapy than unstimulated control cells (Fig. 1a,b). Next, we further analyzed the resistance to radiotherapy. As a result of chemotherapy, stimulated tumor cells demonstrated increased resistance to radiotherapy (Fig. 1c). However, a tendency toward acquired resistance was not demonstrated in cancer cells stimulated with FEF3 cells (CM/NF) as normal fibroblasts (Supplementary Fig. 1). From these results, we planned an in vivo study to confirm the resistance to 5-FU, which is a standard anticancer drug for EC. To evaluate the therapeutic resistance of CAFs in vivo, we compared two groups: TE4 cells inoculated alone vs TE4 and CAFs coinoculated. In the TE4 cells alone group, tumor growth could be suppressed by 5-FU compared with control treatment (39.0% reduction, day 28, P<0.05) (Fig. 1d). However, in the CAF coinoculated group, a significant difference was not observed between the two groups (Fig. 1e), demonstrating acquired resistance to 5-FU in tumor cells cocultured with CAFs. These results indicated that EC tumors can acquire chemoresistance via CAF stimulation during tumor progression.

**CAFs promote a malignant phenotype in tumor cells.** To explore the effects of CAFs on cancer cells with malignant potential, we performed migration, invasion and colony formation assays. The migration assay showed that the number of migrated cancer cells was increased in each cancer cell line for tumor cells stimulated with CM from CAFs (CM/CAF\(^{TE4}\) or CM/CAF\(^{OE19}\)) compared with control tumor cells, whereas migration was not upregulated in cancer cells stimulated with normal fibroblasts (CM/NF) (Fig. 2a). The invasion assay also showed that the number of invaded cancer cells was increased by CM/CAFs in the same manner (Fig. 2b). In the scratch assay, a similar result was demonstrated for cancer cells, which showed faster migration with CAF stimulation than control treatment (Supplementary Fig. 2). The spheroid formation assay showed that cancer cells could make larger spheroids under stimulation with CAFs than under control treatment, demonstrating that spheroid formation was enhanced by CM/CAF, and the effects were strong under conditions of direct contact between cancer cells and CAFs (TE4\(^{DC}\) and OE19\(^{DC}\)) (Fig. 2c). However, we did not find any difference between the groups in terms of the number of the cells (data not shown). Therefore, we further investigated EMT and stem-like phenotypic changes that cause these phenomena in cancer cells induced by CAFs and verified markers using flow cytometry and western blotting (WB). First, we observed morphological changes in cancer cells, demonstrating that the population of tumor cells that had fewer cell junctions and elongated pseudopodia was increased in CAF-treated cells compared with untreated control cells. As expected, these changes were observed to be significant in the context of direct contact between cancer cells and CAFs compared to CM/CAFs treatment (Fig. 2d). To confirm the influence of direct contact between cancer cells and CAFs, cancer cells were separated from the coculture in vitro and analyzed. The populations of CD44- and CD133-, which are considered markers of cancer stem cells, positive cells were analyzed by flow cytometry. Although there was no difference in the CD44-positive cell population in TE4 or OE19 cells or the CD133-positive population in TE4 cells, the OE19 cell population stimulated with CAFs contained significantly more CD133-positive cells (Fig. 2e). Data on CD44 are not shown. WB demonstrated that E-cadherin expression was decreased and vimentin expression was increased in CAF-stimulated cancer cells by direct contact. These changes were observed to be significant following direct contact between cancer cells and CAFs, as determined by flow cytometry (Fig. 2f). Thus, it is suggested that CAFs induce cancer cells to stem cell-like features and EMT, furthermore these malignant changes may indicate some causes of therapeutic resistance. Furthermore, these results for direct contact in vitro can theoretically support the observed therapeutic resistance of coinoculated tumors, as shown in Fig. 1.

**Reversibility of therapeutic resistance following elimination of CAF stimulation.** In advancing therapeutic strategies targeting CAFs, it is necessary to verify whether resistance to anticancer agents can be

---

**References**

1. **Scientific Reports** | (2022) 11:1693 | https://doi.org/10.1038/s41598-021-81465-4
improved by remodeling the tumor stroma or targeting CAFs. We assumed that therapeutic resistance acquired by stimulation with CAFs was reversible and might be improved once the influence of CAFs was eliminated. To verify this theory, we constructed a reverse treatment model, as shown in Fig. 3a. In brief, tumor cells were stimulated with CM from CAFs (CM/CAF) continuously until measurement (labeled TE4CM/CAF or OE19CM/CAF). On the other hand, in the recovered group, each tumor cell was stimulated with CM from CAFs for 2 days. Then, this CM stimulation was stopped, and the medium was changed back to normal medium to eliminate CAF effects (TE4R or OE19R). Although TE4CM/CAF and OE19CM/CAF cells acquired resistance to 5-FU, as in the other experiments, the acquired therapeutic resistance was diminished once stimulation with CM/CAFs was eliminated, as demonstrated in the TE4R and OE19R groups (Fig. 3b). Similar results were found in experiments with docetaxel (Fig. 3c) or radiotherapy (Fig. 3d). In light of these in vitro results, we speculated that CAF elimination could strongly lead to improved therapeutic effects by restructuring the tumor stroma.

FAP-targeted NIR-PIT leads to CAF-specific rapid cell death. To verify whether targeted CAF therapy using the NIR-PIT previously reported by us has similar effects on the cancer cells and fibroblasts used in this study, we first confirmed FAP expression in CAFs educated by cancer cells (TE4 and OE19). Although
**Figure 2.** Tumor cells stimulated with CAFs acquired malignant characteristics. The migration (a) and invasion (b) of esophageal cancer cells cultured with conditioned medium from CAFs were observed and quantified. CAFs enhanced the migration and invasion of cancer cells (scale bar, 100 μm). (c) The results of a spheroid formation assay are shown. Spheroid formation was enhanced by CAFs. The spheroid sizes in the direct-contact (DC) groups were significantly larger than those in the control groups (scale bar, 200 μm). (d) The morphological changes of cancer cells stimulated with CAFs are shown. Compared with untreated control cells, the stimulated tumor cells had a larger population with fewer cell junctions and elongated pseudopodia. These changes were observed more clearly with direct contact between the cancer cells and CAFs (scale bar, 200 μm). (e) The population of CD133-positive cells was analyzed by flow cytometry. A significant difference was not observed in TE4 cells. However, OE19 cells stimulated with CAFs contained more CD133-positive cancer stem-like cells than unstimulated OE19 cells. (f) WB demonstrated that E-cadherin expression was decreased and vimentin expression was increased in CAF-stimulated tumor cells. These changes were observed to be strong in cultures with direct contact between the cancer cells and CAFs. Data are shown as the mean ± SD of three or more independent experiments. Statistical analyses were performed using Dunnett test. **P < 0.01. N.S. indicates no significant difference.
normal fibroblasts expressed FAP mildly, fibroblasts stimulated with cancer medium, CAFs, exhibited strong FAP expression (green) mainly on the cell surface, whereas α-SMA (red) was strongly expressed mainly in the cytoplasm (Fig. 4a). WB showed that the expression of αSMA was increased in CAFs compared to untreated normal fibroblasts and FEF3 cells (Fig. 4b). Similar to the other results, results for flow cytometry analysis demonstrated that the mean fluorescence intensity of FAP was increased in CAFs compared to untreated FEF3 cells (Fig. 4c). Based on these results, we next further confirmed whether FAP-IR700 binds to FAP-expressing cells and evaluated the effect of NIR-PIT on those cells. By fluorescence microscopy, IR-700 (magenta) was observed in the same location as FAP expression on CAFs after conjugation with FAP-IR700, but this was not observed in normal fibroblasts or FEF3 cells (Fig. 4d). To verify the effect of FAP-targeted NIR-PIT, FEF3 cells were conjugated with FAP-IR700 (20 µg/ml) or control agents for 6 h. Then, the fibroblasts were treated with or without 20 J/cm² NIR light irradiation. Most of the CAFs educated by either TE4 or OE19 cells exhibited cell disruption (CAF-TE4: 98.7% reduction, P < 0.01, CAF-OE19: 98.7%, P < 0.01) by FAP-targeted NIR-PIT. A significant difference was not demonstrated with FAP-IR700 alone or irradiation alone (Fig. 5a). Cell viability was decreased in an NIR light dose-dependent manner (Fig. 5b), demonstrating that such a killing effect on CAFs was increased by strong NIR light. On the other hand, FAP-targeted NIR-PIT did not have any effect on cancer cells in a monoculture, showing specific efficacy for FAP-positive cells (Supplementary Fig. 3). In addition, even in the coculture model in vitro, only CAFs seemed to be damaged by NIR-PIT, which caused cell death. We demonstrated PIT-induced cell membrane destruction in targeted cells by confocal microscopy studies. In these assays, FEF3 cells, so-called CAFs in this case, had bleb formation, shrank and were stained by PI, which indicates the induction of cell death. However, cancer cells that did not express FAP were not affected by FAP-targeted NIR-PIT and were not stained by PI (Fig. 5c). This specificity was supported by morphologic changes using microscopy (Supplementary Fig. 4). These results indicated that we successfully eliminated CAFs specifically with the novel targeting therapy FAP-targeted NIR-PIT.

Elimination of CAFs improves resistance to chemotherapy. To evaluate the effect of CAFs-PIT and whether the elimination of CAFs by CAFs-PIT overcomes the therapeutic resistance of tumors in vivo, we estab-
lished CAF coinoculated tumor-bearing mouse models with TE4 cells and compared three groups (the control, 5-FU and 5-FU + NIR-PIT groups). The protocol is shown in Fig. 6a. 5-FU alone could not suppress tumor growth, as shown in Fig. 1e. In marked contrast, combination therapy with 5-FU and NIR-PIT suppressed tumor growth (Fig. 6b, 5-FU: 13.3% reduction, combination of 5-FU and NIR-PIT: 70.9% reduction, day 28, P < 0.01), indicating that elimination of CAFs contributed to the recovery of drug sensitivity and led to tumor suppression. Although it was hypothesized that this method also had some adverse effects, a significant difference in the mean body weight was not found among the groups (Fig. 6c). The reduction in tumor volume mediated by combination therapy with 5-FU and NIR-PIT could clearly be seen macroscopically (Fig. 6d), and the tumors in the combination group demonstrated significantly reduced tumor weights compared with those in the 5-FU
treatment alone group (Fig. 6c, 5-FU: 15.6% reduction, combination of 5-FU and NIR-PIT: 74.4% reduction, day 28, P < 0.01). By immunohistochemical analysis, accumulated CAFs were seen in control and untreated NIR-PIT tumors between the tumor cell clusters. However, an emaciated stroma with some fibroblasts was observed in combination-treated tumors (Fig. 6f). Therefore, it was demonstrated that this combination strategy could suc-

Figure 5. Photoimmunotherapy targeting CAFs expressing FAP induced rapid cell death. (a,b) A cell viability assay was performed with EC cells treated with NIR-PIT. (a) FEF3 were treated with or without 20 J/cm² NIR light irradiation after FAP-IR700 conjugation (20 μg/ml) for 6 h or no conjugation. CAFs were almost dead after conjugation of FAP-IR700 and irradiation. When only FAP-IR700 conjugation or irradiation was performed, CAF viability did not differ significantly. (b) NIR-PIT targeting CAFs was evaluated with various irradiation doses of NIR light. The cell viability of CAFs was decreased in an NIR light dose-dependent manner. (c) IF imaging shows specific rapid cell death induced by NIR-PIT. After an hour of conjugation with FAP-IR700 (10 μg/ml), cells were irradiated with 5 J/cm² NIR light. PI staining indicated that cell membrane destruction was induced by NIR-PIT. CAFs had bleb formation and were stained with PI. Images were acquired at 600 × magnification (a,b; data are shown as the mean ± SD, Dunnett test. *P < 0.05, **P < 0.01.).
cessfully and safely reverse CAF-induced chemoresistance. Furthermore, to exclude the possibility of some effect of NIR irradiation on nontarget cells, we irradiated CAF cocultured tumor model mice with NIR light and treated those mice with 5-FU injection; however, no positive effect of NIR irradiation was observed (Fig. 6g).

**Discussion**

Novel methods for therapy against cancer cells such as molecular targeted therapies, oncolytic viruses, and NIR-PIT have been developed, yet, however, there are still many intractable cancers with a poor prognosis, which are called highly malignant cancers. The main types of these tumors are esophageal, pancreatic and scirrhouss-type gastric cancers, which are cancer types composed of an abundant organized stroma, and the mechanisms of resistance to conventional treatment for such stroma-rich tumors could be as follows: first is therapeutic resistance acquired via the interaction between cancer and stromal cells, second is a reduction in drug delivery efficiency due to an increase in stromal interstitial pressure, and third is promotion of the secretion of cancer-promoting substances by CAFs during DNA-damaging treatment. For those reasons, novel therapy targeting not only cancer cells but also stromal cells are strongly needed to improve outcomes. However, a definitive treatment targeting the tumor stroma has not yet been established.

In this study, we demonstrated that EC cells originating from squamous cell carcinoma or adenoocarcinoma could stimulate fibroblasts into the CAF phenotype, which is the main fibroblast phenotype in the tumor stroma, and furthermore, we suggested that these CAFs influenced cancer cells to develop more malignant phenotypes, which could be related to therapeutic resistance. Although it has already been reported that CAFs originating from tumor tissues exhibit such properties, this is the first report in which the same effects were demonstrated in normal fibroblasts educated by cancer cells. We also showed that the resistance acquired via CAFs could be improved by eliminating CAFs. This reversibility was consistent with the rationale for a therapeutic strategy eliminating CAFs for cancer therapy. In fact, we succeeded in improving the efficacy of chemotherapy by eliminating CAFs by NIR-PIT in vivo, while 5-FU alone had poor efficacy in cocultured tumor-bearing mice. Based on our previous reports, our review on day 21 showed a clear difference in tumor reduction at 21 days between NIR-PIT alone and NIR-PIT with 5-FU: 42.5% reduction vs. 71.4% reduction, respectively, although we did not compare two groups in this research. Therefore, NIR-PIT overcame the resistance of 5-FU, and the therapeutic effect of 5-FU was also added to the NIR-PIT to provide additional tumor suppression. On the other hand, this “CAF targeted therapy” did not affect the cancer cells directly in vitro, as cancer cells did not express FAP (Fig. 5c and Supplementary Fig. 3). According to the observations made after CAFs-PIT, it was confirmed that only cancer cells proliferated in the context of CAF cell death (Supplementary Fig. 4). This suggested that eliminating CAFs may improve resistance to chemotherapy rather than CAFs-targeted NIR-PIT directly affecting cancer cells.

There might be several possibilities to explain why NIR-PIT targeting CAFs improved chemoresistance. First, it has been previously reported that various secreted molecules from CAFs or direct contact between CAFs and cancer cells promotes malignant transformation in cancer cells, leading to the acquisition of EMT markers and a cancer stem-like phenotype, which are known to be factors in chemoresistance; thus, eliminating CAFs may contribute to exhausting this support. Furthermore, Sun et al. reported that stromal fibroblasts were induced to secrete WNT16B by DNA damage due to anticancer drug administration, which directly attenuated the effects of chemotherapy. Huber et al. also reported that glial cell line-derived neurotrophic factor (GDNF) was secreted and induced tumor cell proliferation, invasion and resistance to treatment. All of these secretion processes involve paracrine signaling and act on surrounding cancer cells. Therefore, CAF elimination by NIR-PIT prevents elevated cytokine levels, which promote tumor progression even under conventional therapeutic conditions. Second, an increase in the intratumoral pressure within a tumor may cause a decrease in drug delivery efficiency. Although this study did not directly demonstrate a decrease in the interstitial fluid pressure, it has been reported that reducing the number of physical stromal cells in tumors can reduce the interstitial fluid pressure, increasing the deep penetration of antitumor drugs. Furthermore, CAFs secrete extracellular matrix (ECM) components, such as collagen, proteoglycan and vascular endothelial growth factor (VEGF); thus, the presence of CAFs causes angiogenesis, which is required for abundant stroma and tumor growth. The effect of NIR-PIT is immediate necrosis of target cells, and rapid loss of CAFs may lead to a decrease in the intratumoral pressure due to the loss of a major stromal component and to suppression of subsequent stromal reconstitution by a decrease in VEGF levels. Third, in addition to those reasons, it has been reported that NIR-PIT targeting cancer cells induces perivascular cell death, resulting in massive leakage of nanoparticles into the tumor beds. This phenomenon is called the superenhanced permeation and retention effect (SUPR), and Sano et al. reported that it was more effective than the normal enhanced permeability and retention (EPR) effect. In this study, we used 5-FU, which is a standard EC treatment, and regression of the tumor stroma by NIR-PIT might induce a perivascular SUPR. In that case, using anticancer nanoparticle preparations may produce even stronger antitumor effects. Considering these possibilities, it seems that the intervention of CAFs-PIT before or simultaneous administration of conventional chemotherapy may have a stronger therapeutic effect.

However, it is known that elimination of CAFs is not easily achieved with previous methods. In a phase II trial with metastatic colorectal cancer patients, the enzymatic activity of FAP could not be inhibited, and no efficacy was not demonstrated, although a humanized anti-FAP antibody (mAb F19; sibrotuzumab) was well tolerated. Some reports have investigated novel strategies to inhibit FAP activity; however, these do not control “cellular CAFs” themselves and may have limited efficacy. Furthermore, since it has been reported that mice with knockdown of FAP-positive stromal cells develop cachexia and anemia, the elimination of all FAP-positive CAFs in the body by systematic administration of some drugs could have significant effects on both normal cells and cells in tumor microenvironments. Therefore, a method that specifically controls only FAP-positive CAFs in tumors would be desirable. From the above, the combination of conventional therapy and FAP-targeted NIR-PIT for CAFs is a reasonable and safe strategy. Furthermore, from the original concept, NIR-PIT can be used with
Scientific Reports

Materials and methods

Ethics statement. This study was carried out in accordance with the ethical standards of the Helsinki Declaration II and the ethical guidelines for Medical and Health Research Involving Human Subjects. Mouse experiments were performed in a specific pathogen-free environment at the Okayama University animal facility according to institutional guidelines, and all of animal experimental protocols was approved and reviewed by the Ethics Review Committee for Animal Experimentation of Okayama University, Okayama, Japan. All experiments were performed in accordance with all guidelines and regulations indicated by these committees.

Cell lines and cultures. The human EC cell lines TE4 (HER2-positive squamous cell carcinoma) and OE19 (HER2-positive adenocarcinoma) were used in this study. These cancer cell lines were purchased from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka, Japan). Primary human fetal esophageal fibroblasts (FEF3 cells) were isolated from the human fetal esophagus, and GFP-FEF3 cells were stably transduced with the gene for green fluorescent protein (GFP) as described previously. All cell lines were authenticated by the JCRB Cell Bank (National Institute of Biomedical Innovation, Osaka, Japan) using short tandem repeat analysis. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, MO) in a humidified incubator at 37 °C with 5% CO₂.

Antibodies and reagents. The following antibodies were used in this study: a polyclonal anti-α-SMA antibody (Abcam, Cambridge, UK) for western blotting (WB) and immunofluorescence (IF); an anti-α-SMA mAb (Sigma-Aldrich, St Louis, MO) for immunohistochemistry (IHC); an anti-FAP mAb (Abnova, Taipei, Taiwan) for WB; an anti-FAP mAb (R&D Systems, Minneapolis, MN) for flow cytometry; IF; and IR700-conjugated procedures; an anti-E-cadherin mAb (Cell Signaling Technology, Danvers, MA) for WB; an anti-N-cadherin mAb (Cell Signaling Technology) for WB; an anti-Vimentin mAb (Cell Signaling Technology) for WB; a FITC-conjugated anti-CD44 mAb (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) for flow cytometry; and an APC-conjugated anti-CD133/2 mAb (Miltenyi Biotec GmbH) for flow cytometry; and an anti-β-actin antibody (Sigma-Aldrich) for WB.

Treatment of FEF3 cells with conditioned medium. For preparation of conditioned medium (CM), tumor cells were cultured (in T175 flasks) with DMEM containing 10% FBS. After 24 h, the medium was replaced with DMEM containing 2% FBS, and the cells were incubated. After 2 days, the supernatants were harvested, centrifuged at 1000 rpm for 5 min, and collected. The CM from tumor cells (CM/TE4 or CM/OE19) was stored at −30 °C until use. FEF3 cells were cultured (in T175 flasks) with DMEM containing 10% FBS. After 24 h, the medium was replaced with DMEM containing 2% FBS or CM/TE4 or CM/OE19, and the CMs were incubated for 2 d. These fibroblasts were termed normal FEF3, CAFTE4 or CAFOE19, and the CMs were termed CM/NF, CM/CAFTE4 and CM/CAFOE19, respectively. Supernatants were harvested, centrifuged at 1000 rpm for 5 min and collected as CMs described above. The CM from CAFs was stored at −30 °C until use.

Stimulation of tumor cells. Tumor cells were cultured by three different methods. Tumor cells were cultured with DMEM containing 10% FBS. After 24 h, the medium was replaced with DMEM containing 2% FBS (control) or CM from activated FEF3 cells (CM/CAFTE4 or CM/CAFOE19); these tumor cells were termed TE4CAF or OE19CAF. Cells were stimulated for 4 days. Alternatively, tumor cells and FEF3 cells were mixed and cultured with DMEM containing 10% FBS. After 24 h, the medium was replaced with CM/CAFTE4 or CM/
**Flow cytometry.** Tumor cells were stimulated for 4 days with CM/CAF^{TE4} or CM/CAF^{OE19} (TE4^{CM} or OE19^{CM}) or cocultured with tumor cells and fibroblasts (TE4^{DG} or OE19^{DG}). In the coculture model, tumor cells mixed with FEF3 cells were isolated using anti-ErbB-2 magnetic microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The cells were centrifuged at 300×g for 10 min. The cell pellets were then resuspended in 300 μL of buffer containing a final concentration of 0.5% FBS and 2 mM ethylenediaminetetraacetic acid dissolved in calcium- and magnesium-free phosphate-buffered saline (pH 7.2) and incubated with 100 μL of FeR Blocking Reagent (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and 100 μL of human anti-ErbB-2 microbead-conjugated antibodies for 30 min. The cells were then separated using a MiniMACS cell separator (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). This procedure was repeated three times to improve purity. The expression of CD44 (Miltenyi Biotec GmbH) and CD133 (Miltenyi Biotec GmbH) was analyzed using flow cytometry. FEF3 cells were stimulated with CM from tumor cells (CM/TE4 or CM/OE19) for 2 days. Then, these cells (CAF^{TE4} or CAF^{OE19}) were labeled with a primary mouse anti-FAP antibody (R&D, MAB3715) and FITC-conjugated anti-mouse secondary antibody. The expression of FAP was analyzed using a fluorescence-activated cell sorter.

**Cell viability assay following chemotherapy or radiotherapy.** TE4 and OE19 cells were plated in 96-well microplates (TE4: 3 × 10^3/well, OE19: 5 × 10^3/well) and incubated (at 37 °C with 5% CO_2) for 24 h. Then, the medium was changed to DMEM supplemented with 2% FBS (control), CM from CAFs (CM/CAF^{TE4} or CM/CAF^{OE19}) or normal FEF3 cells (CM/NF), and the cells were cultured for 2 days. The tumor cells cultured with CM/NF were termed TE4^{CM/NF} or OE19^{CM/NF}. After stimulation by culture for 2 days, the tumor cells were treated with the indicated concentrations of 5-fluorouracil (FU) and docetaxel or doses of radiotherapy. Cell proliferation was measured by using water-soluble tetrazolium-1 (WST-1) assays (Roch Diagnostics GmbH, Mannheim, Germany) 3 days after chemotherapy or 5 days after irradiation. WST-1 reagent (10 μL) was added to 100 μL of cell suspension and incubated for 4 h. The absorbance in wells was measured with a microplate reader set at a wavelength of 450 nm with a reference wavelength of 690 nm.

**Migration and invasion assays.** For migration assays, 24-well cell culture inserts with a pore size of 8.0 μm (Falcon, Corning, Corning, NY) were prepared. In the migration assay, tumor cells (1 × 10^5) were seeded in the upper compartment in 500 μL of serum-free DMEM or CM from CAFs (CM/CAF^{TE4} or CM/CAF^{OE19}) or FEF3 cells (CM/NF). The bottom well was filled with 750 μL of DMEM containing 10% FBS. After incubation at 37 °C with 5% CO_2) for 24 h, the cells on the upper surface of the transwell insert were removed using cotton swabs. The migrated cells on the lower surface were stained with crystal violet and observed under a microscope at 200× magnification. In invasion assays, we used transwell inserts coated with Matrigel (Corning), and the subsequent procedures were the same as those for the migration assays. Images were captured in 5 different fields, and the number of cells was then counted visually.

**Scratch assay.** Tumor cells and FEF3 cells were cocultured to 95% confluence in 6-well plates. A wound was made by scratching a line across the bottom of the plate through the confluent cell monolayer using a 200-μL pipette tip. Then, the medium was changed to normal medium (control) or CM from CAFs (CM/CAF^{TE4} or CM/CAF^{OE19}), and the cells were cultured for 2 days. Migratory cells were observed under a microscope (Olympus, Tokyo, Japan).

**Sphere formation assay.** Basement Membrane Matrix Matrigel (Corning, Corning, NY) was placed in 96-well round-bottom microplates (20 μL/well) and solidified (at 37 °C with 5% CO_2) for 30 min. Tumor cells (1 × 10^5/well) and FEF3 cells (5 × 10^5/well) were plated onto the 3D Matrigel and cultured in 2% Matrigel in sequential procedures were the same as those for the migration assays. Images were captured in 5 different fields, and the number of cells was then counted visually.

**Western blot analysis.** Tumor cells were stimulated for 4 days with CM/CAF^{TE4} or CM/CAF^{OE19} (TE4^{CM/CAF} or OE19^{CM/CAF}) or cocultured with fibroblasts (TE4^{DG} or OE19^{DG}). In the coculture model, the tumor cells mixed with FEF3 cells were isolated using the same method as that used for flow cytometry. FEF3 cells were stimulated with CM from tumor cells (CM/TE4 or CM/OE19) for 2 days (CAF^{TE4} or CAF^{OE19}). Primary antibodies against E-cadherin (Cell Signaling Technology), N-cadherin (Cell Signaling Technology), Vimentin (Cell Signaling Technology), αSMA (Abcam), and β-actin (Sigma) were used. Cells were washed, lysed in SDS buffer, and centrifuged. The supernatants were collected and subjected to WB. Proteins were electrophoretically transferred to Hybond-Polyvinylidene difluoride transfer membrane (GE Healthcare Life Science) and incubated with a primary antibody, followed by peroxidase-linked secondary antibodies (Amersham Bioscience). An ECL Prime Western Blotting Detection Reagent (GE Healthcare UK Ltd.) was used to detect the peroxidase activity of the bound antibody.

**Immunofluorescence staining for FAP and α-SMA in FEF3 cells.** FEF3 cells (5 × 10^3/well) were seeded in 4-well chambered slides. After 24 h, the supernatants were replaced with normal medium or CM from
tumor cells (CM/TE4 or CM/OE19), and the cells were cultured for 2 days. After stimulation, the cells were fixed with 4% paraformaldehyde in PBS for 15 min and blocked with 3% bovine serum albumin for 30 min (for FAP staining) or cold 100% methanol for 30 min on ice (for αSMA staining). The slides were incubated with a primary antibody for an hour (FAP; R&D, MAB3715) or overnight (αSMA; Abcam) on ice. After washing twice with PBS, the slides were incubated with the appropriate secondary antibody, FITC-conjugated anti-mouse IgG or Alexa 568-conjugated goat anti-mouse IgG (Invitrogen), for an hour on ice. The slides were further stained with 4,6-diamidino-2-phenylindole (DAPI) and mounted by using Fluorescent Mounting Medium (Dako Cytomation). Then, the cells were analyzed with a confocal laser microscope (FV10i, Olympus, Tokyo, Japan).

Synthesis of FAP-IR700. An anti-FAP antibody (1 mg, R&D, MAB3715) was incubated with IR700 (63.5 μg, 32.5 nmol) in 0.3 mol/L Na2HPO4 (pH 8.5) at room temperature (RT) for 2 h in the dark. The mixture was purified with a Sephacryl G50 column (PD-10; GE Healthcare). The protein concentration was determined with a Bio-Rad protein assay kit (Bio-Rad, CA) by measuring the absorption at 280 nm for FAP mAb and 689 nm for IR700 with spectroscopy. With this sample, the number of fluorophore molecules per FAP mAb was adjusted to approximately 2 (Supplementary Fig. 5). This conjugated antibody was defined as FAP-IR700.

Immunofluorescence staining of FAP-IR700-conjugated FEF3 cells. FEF3 cells (5 × 10^4/well) were seeded on 4-well chambered slides. After 24 h, the supernatants were replaced with normal medium or CM from tumor cells (CM/TE4 or CM/OE19), and the cells were cultured for 2 days. After stimulation, FAP-IR700 was added to the culture medium at 20 μg/mL and incubated for 6 h at 37 °C. Then, the cells were washed with PBS and fixed with 4% paraformaldehyde for 15 min on ice. After washing twice with PBS, the slides were incubated with a FITC-conjugated secondary antibody for an hour on ice. The slides were further stained with DAPI. Then, the cells were analyzed with an FV10i confocal laser microscope. FAP-IR700 could be detected by IR700 fluorescence with a 590- to 650-nm excitation filter and a 665- to 740-nm bandpass emission filter and FITC fluorescence.

Cell viability assay for NIR-PIT. Tumor cells (TE4: 1 × 10^5/well, OE19: 6 × 10^5/well) were plated in 96-well microplates and stimulated with CM from CAFs (CM/CAFTE4 or CM/CAFOE19) or normal medium for 2 days. FEF3 cells (2 × 10^5/well) were plated in 96-well microplates and stimulated with CM from tumor cells (CM/TE4 or CM/OE19) for 4 days. After stimulation, FAP-IR700 was added to the culture medium at 20 μg/mL and incubated for 6 h at 37 °C. After washing cells with PBS, the medium was replaced with normal medium, and NIR light was administrated to the cells with a red light-emitting diode (LED) at 20 J/cm^2 or the indicated intensity (L700-05AU 700 nm, Epitex Co, Kyoto, Japan) with a power density of 15 mW/cm^2 as measured using an optical power meter (PM100, Thorlabs, Inc., Newton, NJ). After exposure to NIR light, cell proliferation was immediately measured by using WST-1 assays, as described above.

Fluorescence microscopy. To detect fibroblast-specific cell death, fluorescence microscopy was performed. Tumor cells (5 × 10^5/well, stained with the CellTracker Blue CMAC dye, 1:400, Invitrogen, Waltham, MA) and GFP-FF3 cells (2.5 × 10^5/well) were plated on 8-well chambered slides and stimulated with CM from tumor cells (CM/TE4 or CM/OE19) for 2 days, as described above. After stimulation, FAP-IR700 was added to the culture medium at 10 μg/mL and incubated for an hour at 37 °C. After conjugation, the medium was replaced with normal medium, and NIR light was administrated to the cells with a red LED at 5 J/cm^2. After 30 min of irradiation, propidium iodide (PI) was added to the medium at an approximate final concentration of 1 μg/mL and incubated at 37 °C for 30 min. The cells were observed with an FV10i confocal laser microscope.

Xenograft tumor model and experiment. All animal studies were approved by the Ethics Review Committee for Animal Experimentation of Okayama University, Okayama, Japan and followed the ARRIVE guidelines for reporting animal research. BALB/c athymic mice (BALB/c-nu/nu) were purchased from Clea (Tokyo, Japan). Six-week-old female mice were used to establish a xenograft tumor model. A total of 3 × 10^6 TE4 cells and 1.5 × 10^6 CAFTE4 cells (stimulated for 4 days, as described above) were suspended in a 50% mixture of Matrigel (Corning, Corning, NY) and inoculated subcutaneously into the right flank.

To evaluate the resistance to chemotherapy, we generated 2 models, mice inoculated with TE4 cells alone and mice co-inoculated with TE4 and CAFTE4 cells (Fig. 1d,e). We randomized the mice used for both models into 2 groups (n = 4/group) after inoculation, and 50 mg/kg 5-FU or PBS was injected intraperitoneally on days 7, 11, and 15. Tumor growth was monitored from day 7 to day 28. To investigate the efficacy of NIR-PIT, mice co-inoculated with TE4 and CAFTE4 cells were randomized into 3 groups (n = 8/group) after inoculation for the following treatments: (1) PBS treatment (control); (2) 5-FU treatment; and (3) 5-FU and NIR-PIT treatment (Fig. 6a–c). Five days after cell inoculation, 100 μg/bf of FAP-IR700 was injected intraperitoneally, and NIR light was administered at 100 J/cm^2 on days 1 and 2 after injection. According to the previous results demonstrated that two NIR light doses kill up to 80% of target-expressing cells, based on the biodistribution of IR700 was high in 24 h after APC injection and decreased over the following days. Irradiation was performed by using an LED light source (L690-66-60 with Lens550; EPITEX, Inc.) with 690 nm as the peak wavelength with a power density of 25 mW/cm^2 as measured using an optical power meter same as in vivo. 50 mg/kg 5-FU or PBS was injected intraperitoneally once a week on the same date as the second irradiation with NIR light. According to the previous results demonstrated that two NIR light doses kill up to 80% of target-expressing cells, based on the biodistribution of IR700 was high in 24 h after APC injection and decreased over the following days. Irradiation was performed by using an LED light source (L690-66-60 with Lens550; EPITEX, Inc.) with 690 nm as the peak wavelength with a power density of 25 mW/cm^2 as measured using an optical power meter same as in vitro. 50 mg/kg 5-FU or PBS was injected intraperitoneally once a week on the same date as the second irradiation with NIR light. Each treatment was performed for three cycles. To eliminate the antitumor effect of NIR light alone on tumors (Fig. 6g), mice co-inoculated with TE4 and CAFTE4 cells were randomized into 3 groups (n = 3 or 4/group) after inoculation for the following treatments: (1) 5-FU treatment; (2) 5-FU and NIR light treatment; and (3) 5-FU and NIR-PIT treatment. Five days after cell inoculation, 100 μg/body of FAP-IR700 was injected intraperitoneally.
NIR light was administered at 100 J/cm² by an LED light source on days 1 and 2 after injection. 50 mg/kg 5-FU was injected intraperitoneally once a week on the same date as the second irradiation with NIR light. Each treatment was performed for three cycles. Tumor volume and body weight were measured once a week. Tumor volumes were estimated using the following formula: V = 1/2 × L × W², where V is the tumor volume, L is the length, and W is the width.

**Immunohistochemical staining.** Resected tumors were fixed in 10% paraformaldehyde and embedded in paraffin. Paraffin sections were immunohistochemically stained. An anti-α-SMA antibody (Sigma) was used for immunohistochemical staining. TE4 and CAF-1 tumors were harvested for histological analysis after treatment. Sections on microslides were deparaffinized with xylene, hydrated using a diluted alcohol series, and immersed in H₂O₂ in methanol to quench endogenous peroxidase activity. The sections were treated with a citrate buffer solution. To reduce nonspecific staining, each section was blocked with Serum-Free Protein Block (Dako, Agilent Technologies, Santa Clara, CA) for 15 min. The sections were then incubated at RT with an anti-SMA antibody (Sigma) diluted in Dako REAL Antibody Diluent (Dako) for 30 min, followed by three washes with buffer. The sections were then incubated with an anti-mouse antibody (EnVision + System/HRP, Mouse (DAB +), Dako) for 30 min at RT. The chromogen used was DAB plus liquid (Dako). The sections were counterstained with Meyer’s hematoxylin, as reported previously⁷,⁴⁷,⁵⁹.

**Statistical analysis.** All statistical analyses were performed with SPSS advanced statistical software (IBM, Chicago, IL, USA). Data are shown as the mean ± standard deviation (SD). A comparison of continuous variables between two groups for in vivo and in vitro assays was performed using a two-sided Student’s t test. For multiple-group comparison, Dunnett test was used. Differences between groups were considered to be statistically significant when the P value was * < 0.05 or ** < 0.01.

**Consent for publication.** All authors read and approved the manuscript. All contributing authors approved the submission of this version of the manuscript and asserted that the document represents valid work. No contributing authors have any disclosures to make.

**Data availability**

The datasets generated and/or analyzed during this study are included in this published article (and its Supplementary files), otherwise available from the corresponding author upon reasonable request.

Received: 31 August 2020; Accepted: 4 January 2021
Published online: 18 January 2021

**References**

1. Blomgren, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. *Nature* **342**, 332–337 (2004).
2. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. *Nat. Rev. Cancer* **6**, 392–401 (2006).
3. Madar, S., Goldstein, I. & Rotter, V. ‘Cancer associated fibroblasts’–more than meets the eye. *Trends Mol. Med.* **19**, 447–453 (2013).
4. Noma, K. et al. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. *Gastroenterology* **134**, 1981–1993 (2008).
5. Harper, J. & Sainson, R. C. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. *Semin. Cancer Biol.* **25**, 69–77 (2014).
6. Yang, L., Pang, Y. & Moses, H. L. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. *Trends Immunol.* **31**, 220–227 (2010).
7. Kato, T. et al. Cancer-associated fibroblasts affect intratumoral CD8(+) and FoxP3(+) T cells Via IL6 in the tumor microenvironment. *Clin. Cancer Res.* **24**, 4820–4833 (2018).
8. Watanabe, M. et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. *Surg. Today* **50**, 12–20 (2020).
9. Tachimori, Y. et al. Comprehensive registry of esophageal cancer in Japan, 2012. *Esophagus* **16**, 221–245 (2019).
10. Chu, Y. et al. Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. *Cell Death Dis.* **9**, 759 (2018).
11. Zhang, H. et al. Cancer-associated Fibroblast-promoted LncRNA DNM3OS confers radioresistance by regulating DNA damage response in esophageal squamous cell carcinoma. *Clin. Cancer Res.* **25**, 1989–2000 (2019).
12. Qiao, Y. et al. IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. *Oncogene* **37**, 873–883 (2018).
13. Ebbing, E. A. et al. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 2237–2242 (2019).
14. Abulaiti, A. et al. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-beta signaling by IL-6. *Lung Cancer (Amsterdam, Netherlands)* **82**, 204–213 (2013).
15. Hasegawa, T. et al. Oncotarget 8, 20741–20750 (2017).
16. Wang, Y. et al. Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. *Cell Death Dis.* **9**, 759 (2018).
17. Wu, X. et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. *Oncotarget* **8**, 20741–20750 (2017).
18. Zhu, Y. et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signaling. *Br. J. Cancer* **110**, 724–732 (2014).
19. Huber, R. M. et al. DNA damage induces GDFN secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance. *Oncotarget* **6**, 2134–2147 (2015).
20. Guo, H. et al. Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. *Cancer Cell Int.* **19**, 347 (2019).
Author contributions
We would also like to thank Ms. Tomoko Sueishi and Ms. Tae Yamanishi for their technical assistance.

Acknowledgements
We would also like to thank Ms. Tomoko Sueishi and Ms. Tae Yamanishi for their technical assistance.

Author contributions
Conception and design: R.K., K.N., T.O., H.K., T.F. Development of methodology: R.K., K.N., H.K., T.F. Acquisition of data (provision of animals, acquisition and management of patients, provision of facilities, etc.): R.K., K.N., H.K., T.O., W.L. & T.J. Cancer-associated fibroblasts in digestive tumors. World J. Gastroenterol. 20, 17804–17818 (2014).

23. Hirata, E. & Sahai, E. Tumor microenvironment and differential responses to therapy. Cold Spring Harb. Perspect. Med. 7, a026781 (2017).

24. Oliver, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).

25. Huang, L., Xu, A. M., Liu, S., Liu, W. & Li, T. J. Cancer-associated fibroblasts in digestive tumors. World J. Gastroenterol. 20, 17804–17818 (2014).

26. Otomo, R. et al. TSPAN12 is a critical factor for cancer-fibroblast cell contact-mediated cancer invasion. Proc. Natl. Acad. Sci. U.S.A. 111, 18689–18696 (2014).

27. Chen, X. & Song, E. Turning foes to friends: Targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99–115 (2019).

28. Kobayashi, H. et al. Cancer-associated fibroblasts in gastrointestinal cancer. Nat. Rev. Gastroenterol. Hepatol. 16, 282–295 (2019).

29. Kelly, T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist. Updates 8, 51–58 (2005).

30. Scanlan, M. J. et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. U.S.A. 91, 5657–5661 (1994).

31. Garin-Chesna, P., Old, L. J. & Retting, W. J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. U.S.A. 87, 7235–7239 (1990).

32. Liu, R., Li, H., Liu, L., Yu, J. & Ren, X. Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol. Ther. 13, 123–129 (2012).

33. Henry, L. R. et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 13, 1736–1741 (2007).

34. Liao, Y., Ni, Y., He, R., Liu, W. & Du, J. Clinical implications of fibroblast activation protein-alpha in non-small cell lung cancer after curative resection: A new predictor for prognosis. J. Cancer Res. Clin. Oncol. 139, 1523–1528 (2013).

35. Shi, M. et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J. Gastroenterol. 18, 840–846 (2012).

36. Kashima, H. et al. Cancer-associated fibroblasts (CAFs) promote the lymph node metastasis of esophageal squamous cell carcinoma. Int. J. Cancer 144, 828–840 (2019).

37. Mitsuhashi, M. et al. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 17, 1685–1691 (2011).

38. Kobayashi, H. & Choyke, P. L. Near-infrared photoimmunotherapy of cancer. Acc. Chem. Res. 52, 2332–2339 (2019).

39. Alsaab, H. O. et al. Progress in clinical trials of photodynamic therapy for solid tumors and the role of nanomedicine. Cancers 12, 2 (2020).

40. Dougherty, T. J. et al. Photodynamic therapy. J. Natl. Cancer Inst. 90, 889–905 (1998).

41. Turubanova, V. D. et al. Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine. J. Immunother. Cancer 7, 350 (2019).

42. Maruoka, Y. et al. Combined CD44- and CD25-targeted near-infrared photoinmunotherapy selectively kills cancer and regulatory T cells in syngeneic mouse cancer models. Cancer Immunol. Immunother. 8, 345–355 (2020).

43. Iobe, Y. et al. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer. EBioMedicine 52, 102632 (2020).

44. Ishida, M. et al. Trastuzumab-based photoinmunotherapy integrated with viral HER2 transduction inhibits peritoneally disseminated HER2-negative cancer. Mol. Cancer Ther. 15, 402–411 (2016).

45. Nagaya, T. et al. Molecularly targeted cancer combination therapy with near-infrared photoinmunotherapy and near-infrared photorelease with duocarmycin-antibody conjugate. Mol. Cancer Ther. 17, 661–670 (2018).

46. Raflkar, R. et al. Epidermal growth factor receptor (EGFR)-targeted photoinmunotherapy (PIT) for the treatment of EGFR-expressing bladder Cancer. Mol. Cancer Ther. 16, 2201–2214 (2017).

47. Watanabe, S. et al. Photoinmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma. Cancer Biol. Ther. 20, 1234–1248 (2019).

48. Lawler, S. E., Speranza, M. C., Cho, C. F. & Chiocca, E. A. Oncolytic viruses in cancer treatment: A review. JAMA Oncol. 3, 841–849 (2017).

49. Lee, Y. T., Tan, Y. J. & Oon, C. E. Molecular targeted therapy: Treating cancer with specificity. Eur. J. Pharmacol. 834, 188–196 (2018).

50. Sun, Y. et al. SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment. Oncogene 35, 4321–4334 (2016).

51. Guo, J., Zeng, H. & Chen, Y. Emerging nano drug delivery systems targeting cancer-associated fibroblasts for improved antitumor effect and tumor drug penetration. Mol. Pharm. 17, 1028–1048 (2020).

52. Sano, K., Nakajima, T., Choyke, P. L. & Kobayashi, H. Markedly enhanced permeability and retention effects induced by photoinmunotherapy of tumors. ACS Nano 7, 717–724 (2013).

53. Ogasawara, K. 8. Revised ethical guidelines for medical and health research involving human subjects. Nihon Hoshusai Gijutsu Gakkai zasshi 73, 397–402 (2017).

54. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671–675 (2012).

55. du Percier Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18, e3000410 (2020).

56. Nagaya, T. et al. Syngeneic mouse models of oral cancer are effectively targeted by anti-CD44-based NIR-PIT. Mol. Cancer Res. 15, 1667–1677 (2017).

57. Mitsuhashi, M., Nakajima, T., Sano, K., Choyke, P. L. & Kobayashi, H. Near-infrared theranostic photoinmunotherapy (PIT): Repeated exposure of light enhances the effect of immunoconjugate. Bioconjug. Chem. 23, 604–609 (2012).

58. Al Shoyaih, A., Archie, S. R. & Karamyan, V. T. Intraperitoneal route of drug administration: Should it be used in experimental animal studies?. Pharm. Res. 37, 12 (2019).

59. Kashima, H. et al. Cancer-associated fibroblasts (CAFs) promote the lymph node metastasis of esophageal squamous cell carcinoma. Int. J. Cancer 144, 828–840 (2018).
N.N., T.K., S.K., H.S. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, and computational analysis): R.K., N.N., T.K., Y.S. Writing, review, and/or revision of the manuscript: R.K., K.N., T.F. Administrative, technical, or material support (i.e., reporting or organizing data and constructing databases): R.K., H.K., K.N., H.T., S.K., H.K., T.F. Study supervision: K.N., S.K., H.T., S.K., H.K., T.F.

Funding
This study was supported by grants-in-aid from the Ministry of Education Culture, Sports, Science and Technology, Japan (to K. Noma, Y. Shirakawa and T. Fujiwara) and grants from the Ministry of Health, Labor and Welfare, Japan (to T. Fujiwara). H. Kobayashi was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-81465-4.

Correspondence and requests for materials should be addressed to K.N.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021